Health Care • Biotechnology: Pharmaceutical Preparations
$60.88 ▲ +0.91
(+1.52%)
MKT CAP: $5.01B • VOL: 1.34M
52W L $59 52W H $91
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$51
MEDIAN
$68
MEAN
$69
HIGH
$83
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE PTCT TAPE
PTCT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $73.66 | $70.01 | 2025-02-14 | $55.40 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $76.71 | $71.84 | 2025-02-06 | $57.23 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $69.40 | $66.97 | 2025-01-29 | $58.44 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $62.10 | — | 2025-01-17 | $59.66 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $53.57 | $57.84 | 2025-01-09 | $54.18 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $72.45 | $63.32 | 2024-12-18 | $52.97 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $59.05 | $61.49 | 2024-12-04 | $56.62 | -4.3% | 48% | C |